



Colibri Heart Valve to Present at the 24th Annual Piper Jaffray Health Care Conference in November and the Texas Cardiovascular Innovative Ventures (TCIV) Conference in December

Colibri strengthens patent portfolio with issuance of second patent

BROOMFIELD, CO – November 20, 2012 – [Colibri Heart Valve](#), LLC, a privately held medical device company, announced that [Joseph B. Horn](#), Colibri's president and chief executive officer, will present a corporate update at the 24th annual Piper Jaffray Health Care Conference on Wednesday, November 28 at 12:10 p.m. Mr. Horn's presentation will include an update on development of Colibri's investigational transcatheter aortic valve implantation (TAVI) device, the world's first and only low -profile, 14 French pre-mounted, pre-crimped, and pre-packaged, ready-for-use, TAVI system.

The Piper Jaffray Health Care Conference is taking place in New York November 27-28, 2012 at the New York Palace Hotel. The conference will feature presentations from executives from the industry's leading public and private companies to an audience of nearly 1,600 attendees, including top institutional investors, equity portfolio managers and research analysts from the United States, Canada, the United Kingdom, Asia and Europe.

Colibri's management team will also present the Texas Cardiovascular Innovative Ventures (TCIV) Conference on Tuesday, December 4 taking place at the Westin Galleria Dallas in Dallas, Texas. The TCIV brings together the optimal audience for advancing the field of cardiovascular innovations. The program attracts emerging cardiovascular companies, regional and national venture capital firms, angel investors, established cardiovascular industry leaders and leading medical analysts seeking their next groundbreaking opportunities.

Colibri recently received an Issue Notification from the U.S. Patent and Trademark Office regarding the granting of U.S. Patent No. 8,308,797 titled, "Percutaneously Implantable Replacement Heart Valve Device And Method Of Making Same." The patent issued on November 13, 2012 and is directed to a percutaneously implantable replacement transcatheter aortic heart valve. The associated patent application (10/887,688) has priority claims with content dating back to January 4, 2002.

About Colibri Heart Valve, LLC and the [Colibri TAVI System](#)

Colibri Heart Valve, LLC is a privately held medical device company based in Broomfield, CO that researches and develops novel heart valve technologies. Colibri has developed a pre-mounted, pre-crimped, and pre-packaged, ready-for-use transcatheter aortic valve implantation (TAVI) device called the “Colibri TAVI System.” TAVI is an important treatment option for heart valve replacement due to its minimally invasive nature, clinical efficacy, extensive patient experience, and reduced procedural costs. Colibri’s advanced technology is a culmination of over 10 years of research and development by Colibri’s founders, Dr. David Paniagua and Dr. R. David Fish into the tissue, valve design, frame, and delivery catheter. The Company’s unique tissue processing method produces extremely strong, durable, and biocompatible tissue. The proprietary tissue enables loading, crimping, and packaging of the Colibri valve at manufacture, making in-procedure valve rinsing and loading at time of use unnecessary. The “Colibri TAVI System” is designed to be shipped ready-for-use.

Colibri’s corporate headquarters and pre-commercialization facilities are located in Broomfield, Colorado with R&D located in Houston, Texas.

For more information, visit: www.colibrihv.com.

Corporate and Media Relations Contact:

Eric Schauble, VP, Corporate Development
Colibri Heart Valve, LLC
Telephone: (303) 460-8667
eschauble@colibrihv.com

Felicia Vonella
Vonella Communications
Telephone: (917) 826-3427
felicia@vonella.com